Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Inclusion criteria

* Age ≥ 16 years
* Newly diagnosed locally advanced or metastatic primary lung cancer (histologically/ cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT
* Ambulatory (receiving outpatient SACT)

Exclusion criteria

* Hypersensitivity to apixaban or to any of the listed SmPC excipients
* Active clinically significant bleeding
* Lesion or condition considered a significant risk factor for major bleeding
* Hepatic disease associated with impaired synthetic function
* Platelet count \< 50 x 109 /L
* Elevated liver enzymes ALT/AST \> 2 x ULN or total bilirubin ≥ 1.5 x ULN
* Renal failure (creatinine clearance \< 15ml/min)
* Weight \< 40kg
* Estimated life expectancy \< 6 months
* Continuous anticoagulation (e.g., unfractionated heparin, low molecular weight heparins, heparin derivatives and oral anticoagulants) for other medical conditions
* The usage of medications contraindicated with apixaban
* Pregnancy
* Breast feeding
* Judgement by the Investigator that the participant is unsuitable to participate in the trial and the participant is unlikely to comply with trial procedures, restrictions and requirements
* Inability to consent
* Receiving SACT for potentially resectable / resectable lung cancer as part of neo-adjuvant or adjuvant treatment
* SACT with significant potential DDI with apixaban (section 7.2.3)